Alpha glucosidase inhibitor voglibose can prevent pioglitazone-induced body weight gain in Type 2 diabetic patients

被引：19
|
作者：
Negishi, Mayumi [1 ,2 ]
Shimomura, Kenju
Proks, Peter [3 ]
Shimomura, Yohnosuke [4 ]
Mori, Masatomo [2 ]
机构：
[1] Gunma Univ, Grad Sch Med, Heisei Hidaka Clin, Med Dept Diabet, Gunma 3700001, Japan
[2] Gunma Univ, Grad Sch Med, Dept Med & Mol Sci, Gunma 3700001, Japan
[3] Univ Oxford, HenryWellcome Ctr Gene Funct, Dept Physiol Anat & Genet, Oxford, England
[4] Gunma Prefectural Coll Hlth Sci, Gunma, Japan
来源：
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY | 2008年 / 66卷 / 02期
关键词：
D O I：
10.1111/j.1365-2125.2008.03216.x
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：318 / 319
页数：2
相关论文
共 50 条
  • [1] Effect of a new alpha-glucosidase inhibitor, Voglibose, in diabetic patients with liver cirrhosis
    Yoshitsugu, M
    Hiyoshi, T
    Akasu, F
    DIABETOLOGIA, 1997, 40 : 1249 - 1249
  • [2] Pioglitazone induced weight changes in type 2 diabetic patients
    Ghosh, Sayantani
    Dey, Saugat
    INTERNATIONAL JOURNAL OF COLLABORATIVE RESEARCH ON INTERNAL MEDICINE & PUBLIC HEALTH, 2011, 3 (06) : 534 - 540
  • [3] Pioglitazone-induced body weight gain is prevented by combined administration with the lipoprotein lipase activator NO-1886
    Kusunoki, Masataka
    Tsutsumi, Kazuhiko
    Sato, Daisuke
    Nakamura, Aki
    Habu, Satoshi
    Mori, Yuichi
    Morishita, Munehiko
    Yonemoto, Takayuki
    Miyata, Tetsuro
    Nakaya, Yutaka
    Nakamura, Takao
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2011, 668 (03) : 486 - 491
  • [4] Protective Effects of Vildagliptin against Pioglitazone-Induced Bone Loss in Type 2 Diabetic Rats
    Eom, Young Sil
    Gwon, A-Ryeong
    Kwak, Kyung Min
    Kim, Ju-Young
    Yu, Seung Hee
    Lee, Sihoon
    Kim, Yeun Sun
    Park, Ie Byung
    Kim, Kwang-Won
    Lee, Kiyoung
    Kim, Byung-Joon
    PLOS ONE, 2016, 11 (12):
  • [5] Alpha-Glucosidase Inhibitor Voglibose Suppresses Azoxymethane-Induced Colonic Preneoplastic Lesions in Diabetic and Obese Mice
    Kato, Junichi
    Shirakami, Yohei
    Mizutani, Taku
    Kubota, Masaya
    Sakai, Hiroyasu
    Ibuka, Takashi
    Shimizu, Masahito
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (06)
  • [6] The novel SGLT-2 inhibitor, empagliflozin, prevents pioglitazone-induced weight gain and further improves glycaemic control in dietary-induced obese rats
    Naderali, E. K.
    Grempler, R.
    Thomas, L.
    Sauer, A.
    Michael, M.
    Eickelmann, P.
    Klein, T.
    Mayoux, E.
    Tahbaz, A.
    DIABETIC MEDICINE, 2014, 31 : 66 - 66
  • [7] Effect of an α-glucosidase inhibitor (voglibose), in combination with sulphonylureas, on glycaemic control in type 2 diabetes patients
    Saito, N
    Sakai, H
    Suzuki, S
    Sekihara, H
    Yajima, Y
    JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 1998, 26 (05) : 219 - 232
  • [8] The Novel SGLT2 Inhibitor BI 10773 Prevents Pioglitazone-Induced Weight Gain and Further Improves Glycemic Control in Dietary-Induced Obese Rats
    Grempler, Rolf
    Thomas, Leo
    Sauer, Achim
    Mark, Michael
    Eickelmann, Peter
    Vickers, Steven
    Cheetham, Sharon C.
    Klein, Thomas
    Jones, Robert B.
    DIABETES, 2011, 60 : A499 - A500
  • [9] Can Pioglitazone Prevent or Delay Type 2 Diabetes in Patients with Prediabetes?
    Obi, Pamela O.
    AMERICAN FAMILY PHYSICIAN, 2021, 104 (02) : 139 - 140
  • [10] An α-glucosidase inhibitor, voglibose, reduces oxidative stress markers and soluble intercellular adhesion molecule 1 in obese type 2 diabetic patients
    Satoh, Noriko
    Shimatsu, Akira
    Yamada, Kazunori
    Aizawa-Abe, Megumi
    Suganami, Takayoshi
    Kuzuya, Hideshi
    Ogawa, Yoshihiro
    METABOLISM-CLINICAL AND EXPERIMENTAL, 2006, 55 (06): : 786 - 793
12345